Immunome (IMNM) catalysts

Upcoming FDA decisions and readouts we track for Immunome, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 11 Sep 2026

FreeBioList tracks 1 upcoming catalyst for Immunome (IMNM, listed on Nasdaq). It concerns Varegacestat (Desmoid tumours).

First on the list: the PDUFA date for Varegacestat (Desmoid tumours), dated 28 Apr 2027.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.

Background reading: What a PDUFA date is, and why the FDA doesn't publish them.

Ticker: IMNM
Next catalyst: 28 Apr 2027
Type: PDUFA date
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Immunome IMNM · Nasdaq	Varegacestat	Desmoid tumours	28 Apr 2027 in 203d	PDUFA date	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states the FDA accepted the NDA "for varegacestat for the treatment of adults with desmoid tumors and assigned a PDUFA target action date of April 28, 2027." Source: 8-K exhibit 99.1, filed 11 Aug 2026 · verified 11 Sep 2026

Also due in Q2 2027

Axsome Therapeutics (AXSM)PDUFA date for AXS-12 (reboxetine), 01 May 2027
Pharvaris N.V. (PHVS)PDUFA date for Deucrictibant IR, 23 Apr 2027
Harmony Biosciences Holdings (HRMY)PDUFA date for Pitolisant GR, 01 Apr 2027
Zenas BioPharma (ZBIO)PDUFA date for Obexelimab, 27 May 2027
Context Therapeutics (CNTX)Phase 1 readout for CTIM-76, Q2 2027